What Is Lexapro Used For? Depression and Anxiety

Lexapro is the brand name for escitalopram, a selective serotonin reuptake inhibitor (SSRI) prescribed primarily for two conditions: major depressive disorder and generalized anxiety disorder. Those are its two FDA-approved uses, though clinicians also prescribe it off-label for other anxiety-related conditions. What makes escitalopram stand out among SSRIs is a body of evidence suggesting it works at least as well as most competitors while causing fewer people to quit treatment due to side effects.

How Escitalopram Works in the Brain

Escitalopram’s main job is to block the serotonin transporter, a protein that pulls serotonin back into nerve cells after it has been released. By blocking that transporter, the drug keeps more serotonin available in the gaps between neurons, which strengthens serotonin signaling over time. That much it shares with every other SSRI on the market. Where escitalopram differs is that it also binds to a separate spot on the same transporter, called an allosteric site. That second binding essentially locks the drug onto the transporter more tightly, slowing its own detachment and making its blockade longer-lasting than you would expect from its concentration alone.¹

Boosting serotonin is only part of the story. Research in animal models shows that escitalopram also triggers changes in proteins tied to neuroplasticity, particularly brain-derived neurotrophic factor (BDNF), which supports the growth and maintenance of nerve connections. These neuroplasticity effects appear at different timepoints depending on the brain region, and they likely contribute to the drug’s longer-term therapeutic benefits beyond simply raising serotonin levels.² This is consistent with the clinical observation that while some patients notice initial improvements within a week or two, the full antidepressant effect often takes four to six weeks to develop.

Treating Major Depressive Disorder

Depression is escitalopram’s most thoroughly studied use. A review of its clinical trial record found that escitalopram was consistently better than placebo and performed as well as or better than other widely used SSRIs, including citalopram, paroxetine, fluoxetine, and sertraline. It also showed advantages over certain serotonin-norepinephrine reuptake inhibitors like duloxetine and extended-release venlafaxine. Continued use after initial improvement helped prevent relapse.³

A more recent meta-analysis pooling 30 head-to-head trials reinforced these findings, showing escitalopram was significantly more effective than citalopram (the drug from which it is chemically derived) at producing both initial treatment response and full remission.⁴ This matters because citalopram and escitalopram are closely related molecules; escitalopram is the purified “left-handed” version of citalopram, and the fact that isolating it produced measurably better outcomes helped establish that the two drugs are not interchangeable.

When depression comes with prominent anxiety symptoms, which is extremely common, the drug still performs well. A 24-week study of patients with major depression accompanied by significant anxiety found that about three-quarters achieved remission (meaning symptoms dropped to minimal levels) by the end of treatment. Roughly 30% of patients had already responded by week two, and the response rate climbed to about 88% by week twelve and held steady from there.⁵ That trajectory is worth knowing about if you are starting the medication, because it means early weeks without obvious improvement are normal and do not necessarily signal that the drug will not work.

Treating Generalized Anxiety Disorder

Generalized anxiety disorder, or GAD, is escitalopram’s other FDA-approved indication. People with GAD experience persistent, hard-to-control worry across many life domains, often accompanied by physical tension, sleep problems, and difficulty concentrating. Escitalopram at doses of 10 to 20 milligrams per day has been tested against placebo in multiple controlled trials, and the drug consistently reduced anxiety scores starting as early as the first or second week of treatment, with improvement continuing through at least eight weeks.⁶

In one trial, the response rate at eight weeks was 68% for people taking escitalopram versus 41% for those on placebo, and the drug was well tolerated with a low rate of people dropping out due to side effects.⁷ Longer-term data show that staying on escitalopram after the initial improvement substantially reduces the chance of relapse. In one relapse-prevention trial, the risk of symptoms returning was roughly four times higher in the group switched to placebo compared with the group that continued escitalopram.⁸ This is a strong argument for continuing treatment for at least several months after you start feeling better, rather than stopping as soon as symptoms ease.

How It Stacks Up Against Other Antidepressants

Two large network meta-analyses published in The Lancet have tried to rank modern antidepressants by both effectiveness and how well patients tolerate them. The first, which compared 12 newer antidepressants, placed escitalopram among the four most effective drugs and identified it along with sertraline as having the best acceptability profile, meaning fewer people quit treatment due to side effects compared with drugs like duloxetine, paroxetine, and venlafaxine.⁹

The second, expanded analysis compared 21 antidepressants and broadly confirmed the picture. Escitalopram was again among the drugs ranked highest for both efficacy and tolerability, a combination that only a handful of the 21 achieved.¹⁰ That said, the actual differences between the top-tier drugs are modest. Escitalopram is not dramatically superior to sertraline or mirtazapine; rather, the evidence consistently places it in the top tier rather than the middle or bottom. For any individual person, the “best” antidepressant is the one that works for them with tolerable side effects, and finding it sometimes takes trial and error.

Side Effects to Expect

Like all SSRIs, escitalopram comes with a predictable set of side effects. Gastrointestinal complaints are among the most common, especially in the first weeks. A systematic review and meta-analysis singled out escitalopram and sertraline as the SSRIs most likely to cause gut-related problems, including nausea, diarrhea, and stomach discomfort (though not constipation or increased appetite).¹¹ For most people these symptoms are worst during the first couple of weeks and then settle down.

Sexual side effects are another well-documented concern with SSRIs as a class. Reduced libido, difficulty reaching orgasm, and other forms of sexual dysfunction may affect a large proportion of users; some estimates suggest that up to 70% of people with depression on serotonin-based antidepressants experience some degree of sexual dysfunction, though separating the drug’s effects from depression itself is difficult.¹² Other side effects that tend to emerge over longer treatment include changes in sleep patterns, sweating, and weight shifts.¹³

One less well-known effect is a mild prolongation of the QT interval on an electrocardiogram, a measure of the heart’s electrical cycle. Pharmacokinetic modeling has estimated the average maximum QT prolongation from escitalopram at about 5 milliseconds, which is small in absolute terms but is the reason regulatory agencies have capped the recommended dose at 20 milligrams per day (and 10 milligrams for older adults).¹⁴ If you already have a heart rhythm condition or take other medications that affect QT interval, your doctor should be aware before prescribing escitalopram.

Off-Label Uses Beyond Depression and Anxiety

Clinicians regularly prescribe escitalopram for conditions that are not part of its official labeling. SSRIs broadly are considered first-line treatment for several anxiety disorders beyond GAD, including social anxiety disorder and panic disorder.¹⁵ Escitalopram has also shown preliminary evidence of benefit in obsessive-compulsive disorder (OCD), driven by its strong serotonin selectivity and the fact that OCD responds to serotonin-based treatment in general.¹⁶ In practice, OCD often requires higher SSRI doses than depression does, and some clinicians prescribe escitalopram above 20 milligrams per day for this purpose, combined with therapy.¹⁷ These higher doses carry additional risk of side effects, including the QT prolongation mentioned earlier, so they require careful monitoring.

Why Medication Plus Therapy Outperforms Either Alone

One of the clearest findings in treatment research is that combining an antidepressant with psychotherapy produces better results than medication by itself. A meta-analysis covering depression, panic disorder, and OCD found that the benefit of combined treatment over pharmacotherapy alone was clinically meaningful, with a number needed to treat of about four. In practical terms, for every four people treated with both medication and therapy instead of medication alone, one additional person achieved a significantly better outcome. The effects of therapy and medication appeared to work through largely independent pathways, each contributing roughly equally, so combining them roughly doubled the overall benefit compared with placebo.¹⁸

This does not mean medication alone is inadequate. Many people do well on escitalopram without concurrent therapy, and not everyone has access to evidence-based psychotherapy. But if you have the option, adding structured therapy, particularly cognitive behavioral therapy, is one of the most reliable ways to improve your outcome.

Special Populations

Pregnancy and Breastfeeding

Decisions about antidepressant use during pregnancy involve weighing the risks of medication exposure against the risks of untreated depression or anxiety to both the parent and the developing baby. A comprehensive review of escitalopram’s safety data found that while some cases of birth defects had been reported after first-trimester exposure, the rates were within the range seen in women who did not take the drug. The review did note an association with certain complications around the time of delivery. No adverse effects were found in the limited studies evaluating breastfeeding.¹⁹ Still, the data on escitalopram specifically during breastfeeding remain thinner than for some older SSRIs.²⁰ This is an area where individual risk-benefit discussions with a prescriber are essential.

Older Adults

Escitalopram is widely used in older adults, and a randomized trial confirmed its benefit for GAD in this population. However, the safety picture deserves extra attention. SSRIs in older patients have been linked to hyponatremia (dangerously low sodium), increased fracture risk, upper gastrointestinal bleeding, and a temporarily elevated suicide risk in the first month of treatment.²¹ The recommended maximum dose for people over 65 is 10 milligrams per day, partly because of the QT prolongation issue and partly because the drug clears more slowly with age.

Stopping Escitalopram Safely

Withdrawal symptoms when stopping an antidepressant are more common than many people expect. At least half of people who discontinue experience some form of withdrawal, and the risk goes up with higher doses, longer treatment duration, and a history of withdrawal from previous attempts.²² Symptoms can include dizziness, electric-shock sensations (“brain zaps”), irritability, insomnia, nausea, and a temporary worsening of mood that is sometimes mistaken for a return of the original condition.

The old standard advice of tapering by halving the dose every couple of weeks often moves too fast, especially in the lower dose ranges. This is because the relationship between dose and the drug’s effect on serotonin receptors is not a straight line; going from 10 milligrams to 5 milligrams removes a larger proportion of the drug’s activity than going from 20 to 15. A pharmacological modeling study found that stretching out doses by skipping days, a common lay strategy, actually makes the problem worse by creating large swings in receptor blockade and increasing withdrawal risk.²³ The preferred approach for people who have been on escitalopram for a long time is very gradual dose reductions, sometimes using liquid formulations to achieve small decrements, with check-ins every two to four weeks and the option to slow down or reverse course if symptoms appear.

When Genetics Affect How You Respond

Escitalopram is processed in the liver primarily by the enzyme CYP2C19, though other enzymes play supporting roles. Genetic variations in these enzymes mean that some people break down the drug faster or slower than average. Someone who is a “poor metabolizer” may end up with higher-than-expected blood levels at a standard dose, increasing side effects, while a “rapid metabolizer” may clear the drug so fast that a normal dose is not enough to be effective.

Pharmacogenomic testing, sometimes marketed under brand names, can identify these metabolizer profiles. In one documented case, testing revealed that a patient was an intermediate metabolizer of the enzyme CYP2B6, which affected the metabolism of multiple SSRIs including escitalopram, and informed a switch to a medication better suited to her genetic profile.²⁴ This kind of testing is not yet standard practice for everyone starting an antidepressant, but it can be especially useful for people who have tried multiple medications without success or who experienced unusual side effects at standard doses. Some insurance plans cover it after a documented treatment failure, and the cost of direct-to-consumer testing has dropped significantly in recent years.

The practical takeaway is not that everyone needs genetic testing before trying escitalopram. Most people do fine at the standard starting dose of 10 milligrams, which can be raised to 20 if needed. But if the drug seems to work poorly or causes disproportionate side effects, genetics is one plausible explanation worth exploring rather than simply cycling through additional medications at random.